top of page

Clinical-Stage Biopharma with a Novel, Targeted Therapy for Brain Tumors

Listing Code:





Pharmaceuticals & Supplements

Asking Price:




Company Overview

PRIME exits and American HealthCare Capital are pleased to introduce a clinical-stage biopharmaceutical business with a novel, patented, small-molecule therapeutic agent for brain cancers. The agent selectively targets and inhibits a transcription factor that is highly expressed in glioblastomas and other tumors of the brain. In tumor cell-based and animal models of glioblastoma, the agent is effective in selectively killing tumor cells, alone and in combination with other targeted therapies. The drug is orally available and has been shown to attain therapeutically relevant concentrations in the brain tissue of non-human primates. The key value drivers for this therapy include:

• Current approaches to treat brain cancers are highly invasive, have significant side effects, and are largely ineffective long term.
• This agent has a high affinity for and selective inhibition of a novel, key transcription factor that is expressed selectively in brain tumors.
• Strong pre-clinical evidence of efficacy and favorable pharmacokinetics in the most relevant models, including oral bioavailability and concentration in brain tissue.
• A favorable pre-clinical safety profile at relevant clinical doses
• A strong intellectual property position with issued patents in the US and all major markets
• An open US IND with orphan drug designation, fast track designation, and rare pediatric disease designation with Phase 1 clinical trials set to begin H2 2024.

The clinical-stage biopharmaceutical business is seeking an acquisition or strategic partnership to fund the significant initial and expanded development programs for this critical therapeutic approach to ensure its rapid availability to patients who need better treatments for brain cancer.

Asking Price

The price and structure of any transaction are to be determined.

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.


2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:


Listing Title:

Clinical-Stage Biopharma with a Novel, Targeted Therapy for Brain Tumors

Heading 4

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi


American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

Join our mailing list to receive our latest news, and listings.

Thanks for submitting!

bottom of page